AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03695705
Drug: Rifaximin 550 mg twice a day and Norfloxacin 400 mg once a day
RxNorm normalized name: rifAXIMin 550 MG
DrugBank: Norfloxacin (DB01059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients on Rifaximin prophylaxis will be given 550 mg twice daily and on Norfloxacin prophylaxis will receive Norfloxacin 400 mg once daily for 6 months
Trial: NCT03078582
Drug: Zilucoplan (RA101495)
RxNorm normalized name: Zilucoplan
DrugBank: Zilucoplan (DB15636)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
Trial: NCT00750126
Drug: Fludarabine, Busulfan, Thymoglobulin
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: study :~* acute and/or chronic graft-versus-host reaction (incidence and severity) and immune reconstitution, post transplantation~* the effectiveness of the protocol on tumor response~* overall survival
Trial: NCT01843348
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01843348
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsules: 0.5 mg, 1 mg or 5 mg. Dosing schedule: transplant to month 2: 4-8ng/ml, month 3 to month 12 3-5 ng/ml according to standard blood levels
Trial: NCT01843348
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules: 10 mg, 25 mg, 50 mg or 100 mg. Transplantation to month 2: 75 - 125 ng/ml, month 3 to month 12: 50 - 100 ng/ml
Trial: NCT01843348
Drug: Mycophenolate mofetil (MMF)
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capsules: 250 or 500 mg. Dosing: duration of study 500 mg bid and no less than 500 mg total daily dose
Trial: NCT01843348
Drug: Simulect
RxNorm normalized name: Simulect
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Lyophilisate in vials with ampoules of sterile water for injection (5 mL), one vial containing 20 mg lyophilisate given intravenously on the day of transplantation and on day four post-transplantation.
Trial: NCT00003014
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00480623
Drug: Satraplatin plus radiation therapy
RxNorm normalized name: satraplatin
DrugBank: Satraplatin (DB04996)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04523402
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with GEMOX regimen before liver resection
Trial: NCT02546349
Drug: fluticasone/salmeterol, tiotropium
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: In group (either high or low eNO), patients will be randomized to receive either 2 puffs of fluticasone/salmeterol 250/25 mcg/puff twice daily or 2 inhalations of tiotropium respimat 2.5 mcg/inhalation once daily for 12 weeks.
Trial: NCT03465436
Drug: Lasmiditan
RxNorm normalized name: lasmiditan
DrugBank: Lasmiditan (DB11732)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg administered orally (PO)
Trial: NCT03465436
Drug: Lasmiditan
RxNorm normalized name: lasmiditan
DrugBank: Lasmiditan (DB11732)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg administered PO
Trial: NCT03465436
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg moxifloxacin administered PO
Trial: NCT02972502
Drug: Metoclopramide
RxNorm normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive 10 mg of intravenous (IV) metoclopramide.
Trial: NCT02972502
Drug: Haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive 2.5 mg of IV haloperidol.
Trial: NCT02972502
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients receive 25 mg of intravenous (IV) diphenhydramine.
Trial: NCT00117403
Drug: Coenzyme Q
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg, compounded as a wafer, two wafers three times per day with meals
Trial: NCT05542979
Drug: HH-003 injection
RxNorm normalized name: HH-009
DrugBank: HH-009 (DB18727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HH-003 injection is administrated via I.V. infusion
Trial: NCT03603938
Drug: potassium losartan
RxNorm normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: treated with bedtime or awakening doses of potassium losartan
Trial: NCT01933464
Drug: Cromolyn Sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03290287
Drug: Aclidinium bromide
RxNorm normalized name: Aclidinium Bromide
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered as monotherapy, concomitant with formoterol not in fixed-dose combination, or fixed-dose aclidinium/formoterol
Trial: NCT03290287
Drug: Other COPD medication
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Users of the following COPD medications:~Tiotropium~Other long-acting anticholinergic (LAMAs): glycopyrronium bromide, umeclidinium~LABA: formoterol, salmeterol, indacaterol~LABA/ICS (LABA in fixed-dose combinations with ICS): formoterol/budesonide, formoterol/beclometasone, formoterol/mometasone, formoterol/fluticasone, salmeterol/fluticasone, and vilanterol/fluticasone.~LAMA/LABA (approved or under regulatory review or in development): glycopyrrolate/formoterol, glycopyrronium/indacaterol, tiotropium/olodaterol, umeclidinium/vilanterol
Trial: NCT04176588
Drug: Etrasimod
RxNorm normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug:Etrasimod Tablet other name:APD334
Trial: NCT01312311
Drug: Docetaxel, Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 35mg/m2 D1 \& D8 Cisplatin 70mg/m2 D1
Trial: NCT01352728
Drug: Axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg daily for 6 cycle with TACE+Axitinib, Axitinib continued until PD.
Trial: NCT00002714
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002714
Drug: mechlorethamine hydrochloride
RxNorm normalized name: Mechlorethamine hydrochloride
DrugBank: Mechlorethamine (DB00888)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002714
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002714
Drug: vinblastine sulfate
RxNorm normalized name: Vinblastine Sulfate
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002714
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00468078
Drug: F-18 FPCIT
RxNorm normalized name: F-18-fpcit
DrugBank: Ioflupane F-18 (DB16913)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mCi, intravenous injection
Trial: NCT02035020
Drug: gamma interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN gamma 1b (Immukin ®) will be administered by subcutaneous route at day 0, 14 and 28 at a dose of 100, 150 and 200 ug respectively.
Trial: NCT03580291
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This group receive oral MMF of 2.0 g / d.
Trial: NCT03763760
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: An intravenous bolus dose of dexamethasone given prior to surgery.
Trial: NCT00563680
Drug: AMG 479
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 479 is a fully human monoclonal antibody (IgG1) against the insulin-like growth factor receptor-1 (IGF-1R). IGF-1R signaling has been shown to play a critical role in the survival of cancer cells. AMG 479 inhibits the binding of both IGF-1 and IGF-2 to IGF-1R, thus inhibiting ligand-dependent receptor activation. Inhibition of IGF-1R signaling with AMG 479 provides a potential mechanism for inhibiting tumor growth and survival.
Trial: NCT00925301
Drug: migalastat hydrochloride
RxNorm normalized name: Migalastat hydrochloride
DrugBank: Migalastat (DB05018)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral capsule QOD
Trial: NCT04465539
Drug: Hydroxyethyl Starch 130-0.4 60 MG/ML [Voluven]
RxNorm normalized name: hydroxyethyl starch 130-0.4 60 MG/ML [Voluven]
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethyl starch dose is 500 cc in 6 hours
Trial: NCT04167176
Drug: Bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% will be included in the injected LA mixture.
Trial: NCT04167176
Drug: Lidocaine 2%
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine 2% will be included in the injected LA mixture.
Trial: NCT00603291
Drug: Lorcaserin 10 mg once daily (QD)
RxNorm normalized name: lisinopril
DrugBank: Lorcaserin (DB04871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lorcaserin 10 mg tablet each morning and placebo tablet each evening for a duration of 52 weeks.
Trial: NCT00603291
Drug: Lorcaserin 10 mg twice a day (BID)
RxNorm normalized name: lorcaserin hydrochloride 10 MG
DrugBank: Lorcaserin (DB04871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lorcaserin 10 mg tablet each morning and evening for a duration of 52 weeks.
Trial: NCT00770692
Drug: Eszopiclone 1 mg- Elderly
RxNorm normalized name: eszopiclone 1 MG
DrugBank: Eszopiclone (DB00402)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elderly participants: Eszopiclone 1 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment.
Trial: NCT00770692
Drug: Eszopiclone 2 mg- Elderly
RxNorm normalized name: eszopiclone 2 MG
DrugBank: Eszopiclone (DB00402)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elderly participants: Eszopiclone 2 mg tablet and 1 tablet placebo 1 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment.
Trial: NCT00770692
Drug: Eszopiclone 3 mg- Non-elderly
RxNorm normalized name: eszopiclone 3 MG
DrugBank: Eszopiclone (DB00402)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-elderly participants: Eszopiclone 3 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment.
Trial: NCT00770692
Drug: Eszopiclone 2 mg- Non-elderly
RxNorm normalized name: eszopiclone 2 MG
DrugBank: Eszopiclone (DB00402)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-elderly participants: Eszopiclone 2 mg tablet and 1 tablet of placebo 3 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment.
Trial: NCT00293202
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Hemodialysis patients will receive Etanercept at a dose of 25 mg by subcutaneous injection twice a week
Trial: NCT01079884
Drug: esomeprazole 40 mg
RxNorm normalized name: esomeprazole 40 MG
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg daily for 4 weeks
Trial: NCT00734201
Drug: V24343
RxNorm normalized name: V24343
DrugBank: V24343 (DB05201)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, 1mg, 2 mg, 5 mg or 25 mg, or placebo, once daily for 28 days
Trial: NCT02059330
Drug: Palbociclib 75mg
RxNorm normalized name: PALBOCICLIB 75MG TAB
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In Period 1, Japanese subjects will receive a single oral 75mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
Trial: NCT02059330
Drug: Palbociclib 125mg
RxNorm normalized name: PALBOCICLIB 125MG TAB
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In Period 2, Japanese subjects will receive a single oral 125mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
Trial: NCT02059330
Drug: Palbociclib 100mg
RxNorm normalized name: PALBOCICLIB 100MG TAB
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In Period 3, Japanese subjects will receive a single oral 100mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
Trial: NCT02059330
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In Period 4, Japanese subjects will receive a single oral dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours. The amount of the dose will be determined based on an interim analysis of the PK data from Periods 1 and 2.
Trial: NCT02059330
Drug: Palbociclib 125mg
RxNorm normalized name: PALBOCICLIB 125MG TAB
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In Period 1, healthy non-Asian subjects will receive a single oral 125mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
Trial: NCT00377936
Drug: Gemcitabine alone
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine monotherapy 1000 mg/m2 weekly
Trial: NCT00377936
Drug: EndoTAG-1 and Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: EndoTAG-1 11 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
Trial: NCT00377936
Drug: EndoTAG-1 and Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: EndoTAG-1 22 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
Trial: NCT00377936
Drug: EndoTAG-1 and Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: EndoTAG-1 44 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
Trial: NCT02213952
Drug: Platelet-Rich Plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For obtaining autologous PRP, will be drawn from 9-30 ml of blood of the patient in sterile tubes containing 4.5 ml of 3.8% sodium citrate. The tubes will be centrifuged for 8 min at 580 Gs to separate the different blood components according to density gradient. After centrifugation, we will aspire the PRP. We will add CaCl2 to the PRP (50l per ml of liquid plasma). While the plasma will get gelified, we will cure the ulcer with saline cleaning and mechanical removal. Then the ulcer will be covered with gelified PRP and a secondary dressing. This cure will be done each 7 days.
Trial: NCT01230892
Drug: Nebivolol
RxNorm normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg PO qday
Trial: NCT01230892
Drug: Atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg PO qday
Trial: NCT01288469
Drug: Alirocumab
RxNorm normalized name: Alirocumab
DrugBank: Alirocumab (DB09302)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One subcutaneous (SC) injection in the abdomen only.
Trial: NCT01288469
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Over-encapsulated tablet orally once daily in the evening with dinner.
Trial: NCT02055014
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00765011
Drug: TPF, radiotherapy and cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 cycles of: cisplatin: 75mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracilo: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy,divided into daily doses of 2 Gray (total days:35) Cetuximab: 400 mg/m2, i.v, 2 hours, 1 day Cetuximab: 250 mg/m2, i.v, 1 hour, 7 days
Trial: NCT02030483
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclb will be given at predefined dose level of 75 mg, 100 mg, 125 mg, or 150 mg days 1-14 every 28 days (days 0-14 for cycle 1 only).
Trial: NCT02030483
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle (Day 1 dosing is omitted for cycle 1 only).
Trial: NCT02030483
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide at predefined dose level of 5mg, 10 mg, 15 mg, 25 mg daily for days 8-21 (or days 1-21, depending on dose level cohort).
Trial: NCT02442271
Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
Trial: NCT02442271
Drug: ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet
Trial: NCT00331071
Drug: Monophasic or triphasic Oral contraceptive tablet
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fourth week is patch free
Trial: NCT04715997
Drug: GX-19N
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen
Trial: NCT03023514
Drug: Vaginal Progesterone
RxNorm normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg Vaginal Progesterone (1 vaginal capsule/24h) from the day of the donors pick up until 8 week of pregnancy
Trial: NCT01023295
Drug: fosbretabulin
RxNorm normalized name: Fosbretabulin
DrugBank: Fosbretabulin (DB12577)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, intravenous infusion
Trial: NCT01023295
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose, intravenous infusion
Trial: NCT00408564
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00408564
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01674413
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab 40 mg q 2 weeks, with placebo loading of 3 syringes/1 syringe at Weeks 0/2, 12/14, 24/26, and 36/38
Trial: NCT03038958
Drug: Isobaric 2-chloroprocaine
RxNorm normalized name: 2-chloroprocaine
DrugBank: Procaine (DB00721)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intrathecal injection of 50 mg isobaric 2-Chloroprocaine
Trial: NCT01674413
Drug: Adalimumab PRN
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 160 mg/80 mg Adalimumab at Weeks 0 and 2, followed by 1 syringe SC placebo q 2 weeks (except at Weeks 12/14, 24/26, and 36/38), with~* PRNLOADing of 160 mg/80 mg Adalimumab at Weeks 12/14, 24/26, or 36/38 if most recent FCP is ≥167 mcg/gram of stool,~* Or, placebo loading of 4 syringes/2 syringes at Weeks 12/14, 24/26, and 36/38 if most recent FCP is \< 167 mcg/gram of stool.
Trial: NCT00621049
Drug: Docetaxel/Carboplatin/Bevacizumab/Erlotinib
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1 Bevacizumab 15mg/kg IV D1~Docetaxel should be administered before carboplatin.~After completion of four cycles of treatment, patients in Cohort A will then proceed with Maintenance treatment defined as follows:~Maintenance Treatment for patients in Cohort A:~Bevacizumab 15mg/kg IV D1 Erlotinib 150mg PO daily~Treatment cycle = 21 days. Patients will complete 8 cycles (24 weeks) of maintenance therapy unless there is evidence of disease recurrence or unacceptable toxicity.
Trial: NCT00621049
Drug: Docetaxel/Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjuvant Treatment Cohort B:~Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1~Docetaxel should be administered before carboplatin.~Treatment cycle = 21 days. Patients in Cohort B will complete 4 cycles of treatment.
Trial: NCT03038958
Drug: Hyperbaric prilocaine
RxNorm normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intrathecal injection of 50 mg hyperbaric prilocaine 2%
Trial: NCT00737282
Drug: Proellex 25 mg
RxNorm normalized name: guaiacolsulfonate / hydrocodone bitartrate Oral Solution [Prolex DH]
DrugBank: Telapristone acetate (DB05253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule Proellex 25 mg administered as daily oral doses for four (4) consecutive months during each treatment cycle